We are delighted to share that Nectin Therapeutics has entered into a significant global license agreement with Immunome, Inc. Through this agreement, Immunome gains exclusive rights to a novel panel of antibodies targeting an undisclosed new target.
Fabian Tenenbaum, CEO of Nectin Therapeutics, expressed, “This partnership not only helps us realize the value of our innovative assets but also allows us to intensify our focus on our pioneering anti-PVR program (NTX1088) as it advances through clinical trials. We’re also excited to move our novel ADCs into clinical development. Immunome’s exceptional track record in developing and commercializing ADC therapies makes them the ideal partner to help bring these assets to their full potential.”
Immunome’s President and CEO, Clay Siegall, PhD, shared, “We are confident that the next wave of transformative antibody-drug conjugates will emerge from novel targets paired with cutting-edge linker-payload technology. We’re eager to build on the foundation Nectin has created with these antibodies and drive them forward.”
Dive into the details of this landmark agreement here: Read More